The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Gain-of-function mutant p53: history and speculation
Abstract
The history of the p53 tumor suppressor (and of the p53 field of research) is quite extraordinary. First discovered in the late 1970s as a protein associated with the SV40 large tumor antigen (and also as a protein that was found in some non-virally transformed cells), p53 was commonly viewed as a facilitator of oncogenic cell transformation (for an excellent review of the early history of p53 see Levine and Oren, 2009). It took nearly 10 years for the cancer research field to realize that wild-type p53 is a tumor suppressor protein. It started in 1989, when Vogelstein and colleagues discovered that deletions, insertions, and point mutations in the TP53 gene were key signatures of colorectal carcinoma (Baker et al., 1989). This was supported by the demonstration that wild-type p53 cloned from non-transformed cells was capable of suppressing the ability of oncogenes to transform cells (Eliyahu et al., 1989; Finlay et al., 1989). Soon thereafter, a flurry of studies including human cancer genetics, mouse models, and cell biology cemented the identity of p53 as a major tumor suppressor. It is now well established that TP53 is mutated with high frequency in more cancers than any other tumor suppressor gene. In fact, the TP53 gene and its protein product(s) are the most well scrutinized entities in cancer biology. For example, at the time of writing this essay, there are 95547 entries in PubMed that have p53 in the title or abstract. International conferences that focus solely on p53, or on mutant p53, or on Mdm2 (the negative regulator of p53), or even on p53 isoforms are held with impressive regularity and are attended by literally hundreds of researchers (Lu, 2017; Lane and Verma, 2019). Central to the p53 story have been the continuous and seminal contributions from Arnold Levine and his trainees, many of whom have gone on to populate the p53 field themselves. The list of critical discoveries that emanated from the Levine lab is long. To name but a few, Levine and colleagues were among the discovers of the protein itself (Linzer and Levine, 1979), were the first successful cloners of the p53 gene (Oren and Levine, 1983), were the first to demonstrate that the wild-type form of the protein suppresses oncogenic transformation (Finlay et al., 1989), and the Levine lab identified Mdm2 as a p53 binding partner that inhibits the function of p53 (Momand et al., 1992). More recently, they have populated the bioinformatics field leading to computational studies that have provided global insights into p53, Mdm2, and their roles in cancer. The discovery that p53 genes isolated from non-transformed normal diploid cells were able to suppress cell transformation posed a dilemma. How was it possible to reconcile earlier findings supporting a pro-oncogenic role for p53? Here too Levine’s group provided the basis for understanding how this quandary could be solved. The changes in TP53 that are found most often in human cancers are called the ‘hot spot’ mutations; these are missense mutations located in the p53 DNA binding domain (reviewed in Freed-Pastor and Prives, 2012). Highly frequent hot spot missense mutations are a key feature of gain-of-function (GOF) oncogenes, while the mutation spectrum of loss-of-function tumor suppressors usually consists of more varied mutation types distributed evenly across the inactivated gene (Vogelstein et al., 2013). This implies that p53 mutation might simply abrogate the wild-type function(s) of the protein, while the hot spot mutants might have gained additional novel oncogenic activities. The GOF hot spot missense mutations for p53 have a loss of sequence-specific DNA binding (Bargonetti et al., 1991; Kern et al., 1991), but they also have characteristics of oncogenes as will be discussed later. These missense p53 hot spot mutations are coupled with the protein retaining all other functional domains (see Figure 1). The Levine team showed that mutations in p53 that activate the ability of p53 to transform cells also increase the half-life of the altered variants (Finlay et al., 1988). This finding helped to explain the high levels of oncogenic mutant p53 (mtp53) found in human cancers (Nigro et al., 1989). The Levine group identified a gained function for p53 by first showing that mtp53 proteins help to transform wild-type p53-expressing cells to become tumorigenic (Hinds et al., 1989, 1990). Domain organization of the p53 protein. The domain boundaries corresponding to human p53 protein are shown with amino acid numbers at bottom. The red outlined boxes show transcription activation domains 1 and 2 (AD1, AD2); the brown outlined box indicates the PR domain; the purple outlined box corresponds to the site-specific DNA binding domain; the non-specific DNA binding carboxyl terminal region comprises the green outlined box that indicates the OD followed by the yellow outlined box containing the lysine-rich 6 K region (CTD). The full sequence of the CTD is shown with the six lysine residues
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies, using either cellular models expressing specific p53 variants or mouse models, suggest an oncogenic GOF for specific p53 variants via the activation of specific pathways associated with metastasis, metabolic reprogramming, or cell differentiation [53].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“, 1989), and the Levine lab identified Mdm2 as a p53 binding partner that inhibits the function of p53 (Momand et al., 1992).”
BackgroundThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Research works printed but not linked: 51
- Aschauer, 2016, Novel targets and interaction partners of mutant p53 gain-of-function, Biochem. Soc. Trans., 44, 460, 10.1042/BST20150261 · DOI
- Baker, 1989, Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma, Science, 244, 217, 10.1126/science.2649981 · DOI · Paper page
- Bargonetti, 1991, Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication, Cell, 65, 1083, 10.1016/0092-8674(91)90560-L · DOI · Paper page
- Bayle, 1995, The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity, Proc. Natl Acad. Sci. USA, 92, 5729, 10.1073/pnas.92.12.5729 · DOI
- Bellazzo, 2018, Complexes formed by mutant p53 and their roles in breast cancer, Breast Cancer, 10, 101
- Dittmer, 1993, Gain of function mutations in p53, Nature Genet., 4, 42, 10.1038/ng0593-42 · DOI · Paper page
- Eliyahu, 1989, Wild-type p53 can inhibit oncogene-mediated focus formation, Proc. Natl Acad. Sci. USA, 86, 8763, 10.1073/pnas.86.22.8763 · DOI · Paper page
- Finlay, 1988, Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life, Mol. Cell. Biol., 8, 531, 10.1128/MCB.8.2.531 · DOI · Paper page
- Fischbach, 2018, The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly(ADP-ribosyl)ation of p53 by PARP1, Nucleic Acids Res., 46, 804, 10.1093/nar/gkx1205 · DOI
- Fischer, 2016, p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis, Cell Cycle, 15, 3210, 10.1080/15384101.2016.1241917 · DOI
- Fischer, 2018, Association between the oligomeric status of p53 and clinical outcomes in Li–Fraumeni syndrome, J. Natl Cancer Inst., 110, 1418, 10.1093/jnci/djy114 · DOI
- Freed-Pastor, 2012, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148, 244, 10.1016/j.cell.2011.12.017 · DOI · Paper page
- Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Gottifredi, 2018, The tip of an iceberg: replication-associated functions of the tumor suppressor p53, Cancers, 10, pii: E250, 10.3390/cancers10080250 · DOI
- Hanzlikova, 2018, The importance of poly(ADP-ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication, Mol. Cell, 71, 319, 10.1016/j.molcel.2018.06.004 · DOI · Paper page
- Hinds, 1989, Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation, J. Virol., 63, 739, 10.1128/JVI.63.2.739-746.1989 · DOI · Paper page
- Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the `hot spot' mutant phenotypes, Cell Growth Differ., 1, 571
- Kern, 1991, Mutant p53 proteins bind DNA abnormally in vitro, Oncogene, 6, 131
- Kim, 2018, Mutant p53 partners in crime, Cell Death Differ., 25, 161, 10.1038/cdd.2017.185 · DOI · Paper page
- Klusmann, 2016, p53 activity results in DNA replication fork processivity, Cell Rep., 17, 1845, 10.1016/j.celrep.2016.10.036 · DOI
- Lane, 2019, p53: updates on mechanisms, biology and therapy (I), J. Mol. Cell Biol., 11, 185, 10.1093/jmcb/mjz017 · DOI
- Laptenko, 2015, The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain, Mol. Cell, 57, 1034, 10.1016/j.molcel.2015.02.015 · DOI · Paper page
- Laptenko, 2016, The tail that wags the dog: how the disordered C-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein, Trends Biochem. Sci., 41, 1022, 10.1016/j.tibs.2016.08.011 · DOI · Paper page
- Lee, 1995, p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches, Cell, 81, 1013, 10.1016/S0092-8674(05)80006-6 · DOI · Paper page
- Li, 2007, Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?, Oncogene, 26, 2220, 10.1038/sj.onc.1210311 · DOI · Paper page
- Lin, 1994, Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein, Genes Dev., 8, 1235, 10.1101/gad.8.10.1235 · DOI · Paper page
- Linzer, 1979, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell, 17, 43, 10.1016/0092-8674(79)90293-9 · DOI · Paper page
- Liu, 2017, Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin, Proc. Natl Acad. Sci. USA, 114, E3766, 10.1073/pnas.1619832114 · DOI
- Lu, 2017, p53 and MDM2: their Yin-Yang intimacy, J. Mol. Cell Biol., 9, 1, 10.1093/jmcb/mjx003 · DOI
- Mantovani, 2019, Mutant p53 as a guardian of the cancer cell, Cell Death Differ., 26, 199, 10.1038/s41418-018-0246-9 · DOI · Paper page
- Miller, 1995, p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner, Mol. Cell. Biol., 15, 6554, 10.1128/MCB.15.12.6554 · DOI
- Morselli, 2008, Mutant p53 protein localized in the cytoplasm inhibits autophagy, Cell Cycle, 7, 3056, 10.4161/cc.7.19.6751 · DOI · Paper page
- Muller, 2013, p53 mutations in cancer, Nat. Cell Biol., 15, 2, 10.1038/ncb2641 · DOI · Paper page
- Nigro, 1989, Mutations in the p53 gene occur in diverse human tumor types, Nature, 342, 705, 10.1038/342705a0 · DOI · Paper page
- Notterman, 1998, Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity, Oncogene, 17, 2743, 10.1038/sj.onc.1202210 · DOI
- Oren, 1983, Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen, Proc. Natl Acad. Sci. USA, 80, 56, 10.1073/pnas.80.1.56 · DOI
- Pfister, 2015, Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells, Genes Dev., 29, 1298, 10.1101/gad.263202.115 · DOI
- Pfister, 2016, Chromatin dysregulation by mutant p53, Oncotarget, 7, 29875, 10.18632/oncotarget.7922 · DOI
- Pfister, 2017, Transcriptional regulation by wild-type and cancer-related mutant forms of p53, Cold Spring Harb. Perspect. Med., 7, pii: a026054, 10.1101/cshperspect.a026054 · DOI
- Polotskaia, 2015, Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4, Proc. Natl Acad. Sci. USA, 112, E1220, 10.1073/pnas.1416318112 · DOI
- Pourebrahim, 2017, Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein, Genes Dev., 31, 1847, 10.1101/gad.304972.117 · DOI
- Qiu, 2017, Identification, validation, and targeting of the mutant p53–PARP–MCM chromatin axis in triple negative breast cancer, NPJ Breast Cancer, 3, pii: 1, 10.1038/s41523-016-0001-7 · DOI
- Raj, 2017, The transactivation domains of the p53 protein, Cold Spring Harb. Perspect. Med., 7, pii: a026047, 10.1101/cshperspect.a026047 · DOI · Paper page
- Roy, 2018, p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways, eLife, 7, pii: e31723, 10.7554/eLife.31723 · DOI
- Scian, 2004, Modulation of gene expression by tumor-derived p53 mutants, Cancer Res., 64, 7447, 10.1158/0008-5472.CAN-04-1568 · DOI
- Shetzer, 2016, Oncogenic mutant p53 gain of function nourishes the vicious cycle of tumor development and cancer stem-cell formation, Cold Spring Harb. Perspect. Med., 6, pii: a026203, 10.1101/cshperspect.a026203 · DOI
- Shtraizent, 2016, Hot spot mutation in TP53 (R248Q) causes oncogenic gain-of-function phenotypes in a breast cancer cell line derived from an African American patient, Int. J. Environ. Res. Public Health, 13, ijerph13010022
- Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
- Yan, 2010, Characterization of functional domains necessary for mutant p53 gain of function, J. Biol. Chem., 285, 14229, 10.1074/jbc.M109.097253 · DOI
- Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251 · DOI · Paper page
- Zhu, 2000, Definition of the p53 functional domains necessary for inducing apoptosis, J. Biol. Chem., 275, 39927, 10.1074/jbc.M005676200 · DOI
Cited by
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Vodicka, P., Andera, L., Opattova, A., & Vodickova, L. (2021) · Cancers · doi:10.3390/cancers13030479 · Cited by 39
“GOF mutations are characterized by a loss of sequence-specific DNA binding and they revert the p53 function from tumor suppressor to oncogene [70], ultimately promoting cell transformation, tumor progression, metastasis, and chemoresistance.”
BackgroundMenendez, D., Anand, J. R., Murphy, C. C., Bell, W. J., Fu, J., Slepushkina, N., Buehler, E., Martin, S. E., Lal-Nag, M., Nitiss, J. L., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28195 · Cited by 22
Metadata
- Authors
- Bargonetti, J., & Prives, C.
- Affiliations
- Department of Biological Sciences Hunter College and The Graduate Center, City University of New York, New York, NY 10021, USA
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07
- Volume
- 11
- Issue
- 7
- Pages
- 605-609
- ISSN
- 1759-4685
- Cited by
- 88
- References
- 4
- Language
- en
- Funders
- Breast Cancer Research Foundation (BCRF-18-011)
- National Institutes of Health-National Cancer Institute (CA87497)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.